Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.61
+0.4%
$1.71
$0.99
$8.77
$82.71M2.71.66 million shs930,473 shs
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$19.68
$11.48
$19.75
$384.69M1.35129,776 shs8,375 shs
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$0.35
$0.03
$3.17
$3.50M0.497.01 million shs61.02 million shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
$1.48
$1.65
$0.82
$3.88
$58.11M1.95494,777 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%+2.29%-27.33%+44.68%-78.73%
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00%0.00%0.00%0.00%0.00%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
0.00%0.00%0.00%0.00%-94.36%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1.5533 of 5 stars
3.52.00.00.00.00.80.6
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.696 of 5 stars
0.00.00.04.70.02.50.0
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43798.42% Upside
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
0.00
N/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
2.50
Moderate Buy$2.17∞ Upside
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TCRR, GRTS, CBMG, HARP, and CABA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
$340K0.00N/AN/A$2.89 per share0.00
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$496K0.00N/AN/A$0.54 per share0.00
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/A$2.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/A

Latest TCRR, GRTS, CBMG, HARP, and CABA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
N/A
0.47
0.47
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
1.83
2.54
2.54
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/A
2.96
2.96

Institutional Ownership

CompanyInstitutional Ownership
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21.98%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
48.46%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
74.01%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
64.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
Cellular Biomedicine Group, Inc. stock logo
CBMG
Cellular Biomedicine Group
21719.48 millionN/AOptionable
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
190108.57 million111.84 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
13739.26 million29.44 millionNot Optionable

Recent News About These Companies

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
Mizuho Downgrades Tcr2 Therapeutics (TCRR)
4 Analysts Have This to Say About TCR2 Therapeutics
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.61 +0.01 (+0.38%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$1.64 +0.04 (+2.43%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cellular Biomedicine Group stock logo

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Gritstone bio stock logo

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

TCR2 Therapeutics stock logo

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.